医学
狼牙棒
心脏病学
内科学
射血分数
心力衰竭
比例危险模型
人口
舒张期
血压
心肌梗塞
经皮冠状动脉介入治疗
环境卫生
作者
Cristina De Colle,Pasquale Paolisso,Emanuele Gallinoro,Dario Tino Bertolone,Niya Mileva,Davide Fabbricatore,Chiara Valeriano,Costantino Mancusi,Carlos Collet,Marc Vanderheyden,Nicola De Luca,Guy Van Camp,Emanuele Barbato,J Bartunek,Martin Pěnička
标识
DOI:10.1093/eurheartj/ehac544.774
摘要
Abstract Background Aortic Regurgitation (AR) may aggravate the clinical course in patients with heart failure and preserved ejection fraction (HFpEF) by increasing filling pressures and triggering LV remodelling. Objective To assess AR's prevalence and long-term prognostic implications in patients with HFpEF. Methods The study population consisted of 458 consecutive patients (age 77.5±9.2 y, 57.9% females) hospitalized with de novo or worsened HFpEF. Patients with more than moderate aortic and/or mitral valve disease were excluded. Data on cardiovascular death, HF re-hospitalization and their composite (MACE) were collected. Results Out of 309 (67.5%) patients with any AR, 156 (34.0%) and 153 (33.5%) had mild-AR and moderate-AR, respectively. The remaining 149 (32.5%) individuals had no-AR. Patients with versus without AR were significantly older with larger LV and LA volumes and a higher prevalence of diastolic dysfunction (all p<0.05). During a median follow-up of 33±25 months, a total of 114 patients (24.9%) died from cardiovascular causes, 126 patients (27.5%) were re-hospitalized for HF, while 272 (59.4%) had the composite endpoint (MACE). In multivariable Cox regression analysis, any AR emerged as an only independent predictor of MACE (HR=1.90, 95% CI 1.26–2.87, p=0.002). Mild-AR and Moderate AR increased the risk of MACE by 77% and 92%, respectively, compared to the No-AR (Figure). Conclusions In patients with HFpEF, mild-to-moderate AR is highly prevalent, and it seems to identify individuals with worse long-term outcomes. This suggests that even mild AR should be considered a high-risk prognostic marker in patients with HFpEF. Funding Acknowledgement Type of funding sources: None.
科研通智能强力驱动
Strongly Powered by AbleSci AI